Binimetinib + Encorafenib for Pancreatic Cancer
Recruiting in Palo Alto (17 mi)
+4 other locations
Overseen byAndrew E Hendifar
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Academic and Community Cancer Research United
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This trial studies how well the combination of binimetinib and encorafenib works in treating patients with pancreatic cancer that has a specific genetic mutation. These medications aim to stop cancer cells from growing by blocking certain enzymes they need. The trial targets patients whose cancer may not respond well to usual treatments. Encorafenib and binimetinib have shown substantial antitumor activity in melanoma, particularly in combination therapy.
Eligibility Criteria
This trial is for adults with pancreatic cancer that has a specific mutation (BRAF V600E). Participants must have had previous treatment, be able to swallow pills, and provide consent. They should not be pregnant or nursing and must agree to use contraception. People with certain health conditions or those taking prohibited medications are excluded.Inclusion Criteria
Your local pathology lab has confirmed that you have pancreatic cancer.
Women who could become pregnant need to have a negative pregnancy test within 7 days before joining the study.
You have a specific BRAF V600E mutation in your tumor.
See 16 more
Exclusion Criteria
Pregnant women
Nursing women
Men or women of childbearing potential who are unwilling to employ adequate contraception
See 24 more
Treatment Details
Interventions
- Binimetinib and Encorafenib (Kinase Inhibitor)
Trial OverviewThe effectiveness of two drugs, Binimetinib and Encorafenib, is being tested on patients with pancreatic cancer carrying the BRAF V600E mutation. The study aims to see if these drugs can stop tumor growth better than standard treatments by blocking enzymes needed for cell growth.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (encorafenib, binimetinib)Experimental Treatment2 Interventions
Patients receive encorafenib PO QD and binimetinib PO BID on days 1-25. Treatment repeats every 28 days for up to 36 cycles in the absence of disease progression or unacceptable toxicity.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Mayo ClinicRochester, MN
Cedars Sinai Medical CenterLos Angeles, CA
Johns Hopkins University/Sidney Kimmel Cancer CenterBaltimore, MD
Mayo Clinic in ArizonaPhoenix, AZ
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Academic and Community Cancer Research UnitedLead Sponsor
National Cancer Institute (NCI)Collaborator